FDA Greenlights Neuroelectrics To Help Patients With Major Depression At Home Amidst Covid-19 Restrictions

shop-mgr2022-12-28T10:18:59+08:00 Neuroelectrics has developed a novel platform to provide personalized therapies for brain disorders using non-invasive brain stimulation Neuroelectrics has received approval by the FDA to conduct a clinical trial of brain stimulation therapy at home through telemedicine for patients with Major Depressive Depression (MDD) By moving into MDD, Neuroelectrics expands their pipeline and current suite of neurodegenerative products into neuropsychiatry Cambridge, MA, USA and Barcelona, SP, May 15th: Today Neuroelectrics announced that the FDA has approved the Investigational Device Exemption supplemental protocol study submitted by Neuroelectrics to help patients with Major Depression Disorder (MDD) that cannot access their current non-invasive brain stimulation treatment (rTMS*...